Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Innogen Pharmaceuticals Enters into Licensing Agreement with Arcera Life Sciences for Efsubaglutide Alfa, Accelerating International Expansion


      News provided by

      Innogen Pharmaceuticals

      Nov 19, 2026, 05:05 ET

      Share this article

      Share this article


      • Under the agreement, Arcera will obtain exclusive rights to Efsubaglutide Alfa in selected countries in Africa, Latin America, the Middle East and Eastern Europe, while Innogen retains the relevant rights in the rest of the world.
      • Under the agreement, Innogen will receive US$38 million in upfront and near-term milestone payments, including a non-refundable upfront payment of US$15 million, as well as sales milestone payments and tiered royalties at rates of up to double-digit percentage based on aggregate annual net sales of the Product in the Territory. The total potential deal value is over US$1 billion.
      • The collaboration marks an important step in bringing a China-developed and commercialized innovative GLP-1 therapy to international markets and will further advance Innogen's global strategy.

      HONG KONG and ABU DHABI, UAE, Nov. 19, 2026 /PRNewswire/ -- Innogen Pharmaceuticals ("Innogen", HKEX: 2591) today announced that it has entered into an exclusive licensing and commercialization agreement with Arcera Life Sciences Ltd. ("Arcera") for the development and commercialization of its internally developed innovative product Efsubaglutide Alfa, in international markets.

      The collaboration represents an important milestone in the international development of Efsubaglutide Alfa and a significant step forward in Innogen's global expansion strategy. It also highlights the potential for China-originated innovation to move beyond domestic commercialization and reach international markets.

      Under the agreement, Arcera will obtain exclusive rights to Efsubaglutide Alfa in selected countries within Africa, Eastern Europe, Latin America, and the Middle East, while Innogen retains the relevant rights in the rest of the world. According to the International Diabetes Federation (IDF), approximately 589 million adults worldwide are living with diabetes, a figure projected to rise to 853 million by 2050. The World Health Organization (WHO) reports that more than one billion people worldwide are living with obesity. As the health burden associated with diabetes, obesity and related metabolic diseases continues to draw attention, demand for innovative treatment options is becoming increasingly evident. Through this collaboration, the two companies will leverage their respective strengths in innovative drug development, international regulatory affairs, market access and commercialization to advance the development and commercialization of Efsubaglutide Alfa in the licensed territories and expand local patients' access to innovative treatment options.

      Efsubaglutide Alfa is a fusion protein comprising a human GLP-1 analogue and an IgG Fc fragment. It has an average half-life of up to 280 hours across different studies. Clinical studies have shown that monotherapy with Efsubaglutide Alfa reduced HbA1c by 1.1 percentage points after four weeks, with a reduction of up to 2.2 percentage points at Week 24, and that it may also help protect pancreatic beta-cell function. Efsubaglutide Alfa has also shown promising clinical development potential in obesity and related metabolic diseases. In the Phase IIb ENLIGHT study in Chinese adults with overweight or obesity, participants receiving 20 mg once weekly (QW) for 18 weeks achieved an average body-weight reduction of 10.6% and a waist-circumference reduction of approximately 8.9 cm. The group receiving 20 mg once every two weeks (Q2W) achieved an average body-weight reduction of 9.7%.

      The study also observed improvements in body-composition. The muscle-to-fat ratio increased by up to 45.3% from baseline with QW dosing, with weight loss driven predominantly by a reduction in fat mass, indicating fat reduction with relative preservation of muscle. Liver fat content was reduced by up to 51.8% with QW dosing. The incidence of gastrointestinal adverse events were low relative to other GLP-1 receptor agonists (based on cross-trial comparisons), no participants discontinued treatment due to adverse events during the 18-week treatment period, and the treatment was well tolerated. Innogen has also completed a Phase II clinical trial in adults with overweight or obesity in Australia, evaluating the efficacy and safety of once-monthly (Q4W) dosing. The study generated further clinical evidence to support the product's future global registration and commercialization.

      Dr. Qinghua Wang, Founder, Chairman and Chief Executive Officer of Innogen Pharmaceuticals said: "We are delighted to establish this collaboration with Arcera, which represents an important step in Innogen's international expansion. We believe that combining world-class science with entrepreneurial innovation is key to improving patient care. Innogen's mission is to provide best-in-class and first-in-class therapies for people living with diabetes, obesity and other metabolic diseases worldwide. Our collaboration with Arcera is an important step toward this vision. By combining Innogen's scientific innovation with Arcera's strengths in international regulatory affairs and commercialization, we aim to broaden access to differentiated therapies and ultimately improve the quality of life of patients around the world."

      Isabel Afonso, Chief Executive Officer of Arcera Life Sciences, said: "Cardiometabolic diseases remain among the most pressing healthcare challenges in the markets we serve. Our agreement with Innogen accelerates the bridge we are building between China and our international markets to bring innovative medicines to more patients and strengthen our cardiometabolic portfolio. By combining our partners' scientific capabilities with Arcera's regulatory expertise, market access and overall commercial reach, we aim to turn innovation into meaningful impact for people living with chronic disease."

      About Innogen Pharmaceuticals

      Founded in 2014, Innogen Pharmaceuticals (HKEX: 2591) is a biopharmaceutical company focused on the research, development and industrialization of innovative medicines for metabolic diseases. The Company has a wholly self-developed pipeline covering indications including type 2 diabetes (T2D), type 1 diabetes (T1D), obesity, metabolic dysfunction-associated steatohepatitis (MASH) and Alzheimer's disease (AD), supported by global intellectual property rights and a global patent portfolio. Its core product, Efsubaglutide Alfa, is a next-generation, human-derived, ultra-long-acting GLP-1 receptor agonist developed in-house. It has been approved for the treatment of T2D in mainland China and Macao, China, and has been included in China's National Reimbursement Drug List (2025 Version). Development of the product received support under China's 13th Five-Year Plan Major New Drug Innovation program. It has also received the First Prize of the Science and Technology Award of the Chinese Pharmaceutical Association and the First Prize of the Science and Technology Award of the Shanghai Pharmaceutical Association. Innogen has entered the stage of global development and regulatory registration, and its manufacturing facilities have obtained PIC/S GMP certification. The Company is committed to providing better treatment options for patients worldwide. For more information, please visit www.innogenpharm.com.

      About Arcera Life Sciences

      Arcera Life Sciences is an international life sciences company headquartered in Abu Dhabi, United Arab Emirates. Arcera brings innovative and proven medicines to patients in over 100 countries worldwide, with operations spanning Africa, Eurasia, Latin America, and the Middle East. Arcera commercializes medicines and healthcare products across multiple therapeutic areas, supported by manufacturing and packaging capabilities in eight countries. To expand access to innovative therapies, Arcera partners with leading pharmaceutical and biotech companies, ensuring supply resilience and quality standards. Its portfolio comprises over 2,000 product presentations marketed under 300+ brands in more than 60 direct markets. To learn more about Arcera, visit www.arceralifesciences.com.

      SOURCE Innogen Pharmaceuticals

      Modal title

      Also from this source

      Innogen Pharmaceuticals Receives PIC/S GMP Certificatation, Accelerating Global Expansion of Efsubaglutide Alfa

      Innogen Pharmaceuticals (HK.2591), a biopharmaceutical company dedicated to innovative drug discovery and industrialization in metabolic diseases,...

      Innogen Pharmaceutical Group Highlights China-Originated Innovation and Global Development Strategy at DIA Global Annual Meeting 2026 China Town Hall

      Innogen Pharmaceutical Group Highlights China-Originated Innovation and Global Development Strategy at DIA Global Annual Meeting 2026 China Town Hall

      During the DIA Global Annual Meeting 2026 held in Philadelphia, the China Town Hall session was successfully convened, bringing together regulatory,...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Biotechnology

      Biotechnology

      Pharmaceuticals

      Pharmaceuticals

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.